CSOWM CERTIFICATION EVALUATION
FULL QUESTIONS AND CORRECT ANSWERS
ALREADY PASSED
●● Physical Activity for Adults with DM
Answer: 150 min of moderate to vigorous aerobic activity weekly (over
at least 3 days)
no more than 2 consecutive days w/o activity
75 min of vigorous aerobic activity weekly (if appropriate)
2-3 weekly sessions of resistance exercise on non consecutive days
all adults should decrease sedentary time (interrupt every 30 min for BG
benefit)
flexibility & balance training recommended 2-3 times weekly for older
adults with DM
●● Potential contraindications for diabetes and exercise
Answer: Retinopathy (risk of vitreous hemorrhage or retinal
detachment)
,Peripheral neuropathy (exam feet, wear protection)
Autonomic neuropathy (thorough cardiac eval)
Diabetic kidney disease (acutely increase urinate albumin excretion) ,
however no specific exercise restrictions needed.
●● DM and Psychosocial Care
Answer: Should be integrated with a pt-centered approach and provided
to all people diagnosed
may include attitudes, expectations with meds and outcomes, affect or
mood, QOL, resources like financial, social, and emotional, and
psychiatric history
●● Critical times to evaluate DSMES
Answer: 1. At diagnosis
2. Annually
3. When complications arise
4. When transitions in care occur
●● Behavior Management for Diabetics
,Answer: DSMES
MNT
Physical Activity
Smoking cessation
Psychosocial care
●● Pharmacotherapy for type 2 DM
Answer: Metformin initially (low cost)
Early insulin if evidence of catabolism, hyperglycemia, and A1c > 10%
SGLT-2 inhibitors or GLP-1 agonist in patients with CVD, kidney dx, or
heart failure
●● DPP-4 inhibitors
Answer: weight neutral type II DM medication
ends in -gliptin
(Januvia)
Better GI tolerability over Metformin
●● Type II DM Meds that cause weight gain
Answer: Thiazolidinediones (low cost)
, Sulfonylureas (Glyburide, Glipizide, Glimepiride) (low cost)
Insulin
●● GLP-1 Agonists
Answer: Liraglutide (Victoza, Saxenda)
Semaglutide (Ozempic, Wegovy)
Exenatide
Dulaglutide (Trulicity)
Injections that affect POMC neurons and cause satiety
●● SGLT2 inhibitors
Answer: Canagliflozin (Invokana)
Dapagliflozin (Farxiga)
Empagliflozin (Jardiance)
prevents reabsorptions of glucose as well as water in the renal tubules
●● Assessment of Obesity Management in Type II DM
Answer: Annual BMI calculations (more frequently if necessary)
FULL QUESTIONS AND CORRECT ANSWERS
ALREADY PASSED
●● Physical Activity for Adults with DM
Answer: 150 min of moderate to vigorous aerobic activity weekly (over
at least 3 days)
no more than 2 consecutive days w/o activity
75 min of vigorous aerobic activity weekly (if appropriate)
2-3 weekly sessions of resistance exercise on non consecutive days
all adults should decrease sedentary time (interrupt every 30 min for BG
benefit)
flexibility & balance training recommended 2-3 times weekly for older
adults with DM
●● Potential contraindications for diabetes and exercise
Answer: Retinopathy (risk of vitreous hemorrhage or retinal
detachment)
,Peripheral neuropathy (exam feet, wear protection)
Autonomic neuropathy (thorough cardiac eval)
Diabetic kidney disease (acutely increase urinate albumin excretion) ,
however no specific exercise restrictions needed.
●● DM and Psychosocial Care
Answer: Should be integrated with a pt-centered approach and provided
to all people diagnosed
may include attitudes, expectations with meds and outcomes, affect or
mood, QOL, resources like financial, social, and emotional, and
psychiatric history
●● Critical times to evaluate DSMES
Answer: 1. At diagnosis
2. Annually
3. When complications arise
4. When transitions in care occur
●● Behavior Management for Diabetics
,Answer: DSMES
MNT
Physical Activity
Smoking cessation
Psychosocial care
●● Pharmacotherapy for type 2 DM
Answer: Metformin initially (low cost)
Early insulin if evidence of catabolism, hyperglycemia, and A1c > 10%
SGLT-2 inhibitors or GLP-1 agonist in patients with CVD, kidney dx, or
heart failure
●● DPP-4 inhibitors
Answer: weight neutral type II DM medication
ends in -gliptin
(Januvia)
Better GI tolerability over Metformin
●● Type II DM Meds that cause weight gain
Answer: Thiazolidinediones (low cost)
, Sulfonylureas (Glyburide, Glipizide, Glimepiride) (low cost)
Insulin
●● GLP-1 Agonists
Answer: Liraglutide (Victoza, Saxenda)
Semaglutide (Ozempic, Wegovy)
Exenatide
Dulaglutide (Trulicity)
Injections that affect POMC neurons and cause satiety
●● SGLT2 inhibitors
Answer: Canagliflozin (Invokana)
Dapagliflozin (Farxiga)
Empagliflozin (Jardiance)
prevents reabsorptions of glucose as well as water in the renal tubules
●● Assessment of Obesity Management in Type II DM
Answer: Annual BMI calculations (more frequently if necessary)
